Clinical Trials
22 trialsNCT05133440 2026-04-28
A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03304418 2025-04-30
RROPE
University of Utah
Phase 2 Completed
NCT03093428 2025-03-28
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03002220 2024-12-11
EXCAAPE
MedSIR
Phase 2 Completed
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT02258451 2023-11-24
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Bayer
Phase 2 Completed
NCT00337155 2023-11-02
BAY88-8223, Dose Finding Study in Patients With HRPC
Bayer
Phase 2 Completed
NCT00667199 2023-04-19
BAY88-8223, Does Response Study in HRPC Patients
Bayer
Phase 2 Completed
NCT02346526 2022-09-29
A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT02366130 2021-10-07
Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03062254 2021-09-21
Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Completed
NCT02463799 2021-07-08
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02283749 2021-02-02
BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Brown University
Phase 2 Completed
NCT02199197 2020-10-30
Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
University of Utah
Phase 2 Completed
NCT02034552 2019-07-23
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
Bayer
Phase 2 Completed
NCT02023697 2019-07-12
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
Bayer
Phase 2 Completed
NCT02390934 2019-06-11
RAD-THYR
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT02507570 2019-03-19
Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis
Carolina Research Professionals, LLC
Phase 2 Completed
NCT01929655 2018-04-24
Japanese BAY88-8223 Monotherapy Phase II Study
Bayer
Phase 2 Completed
NCT02097303 2018-02-01
eRADicAte
Carolina Research Professionals, LLC
Phase 2 Completed
NCT00459654 2014-06-25
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
Bayer
Phase 2 Completed
NCT01070485 2014-06-25
BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease
Bayer
Phase 2 Completed